|
|
SLA-LSQ |
|
Vaxjo ID |
194 |
|
Vaccine Adjuvant Name |
SLA-LSQ |
|
Adjuvant VO ID |
VO_0005422
|
|
Description |
iposome formulation containing the toll-like receptor 4 (TLR4) agonist, second-generation lipid adjuvant (SLA) with Quillaja saponaria 21 (QS-21) that induces Th1 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
3 |
|
Second Host Species for Testing |
16 |
|
Components |
SLA, QS-21, neutral lipid 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) |
|
Storage |
2-8C |
|
Preparation |
liposome formulation using SLA and QS-21 |
|
Function |
innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=64]
Swart et al., 2023: Swart M, Kuipers H, Milder F, Jongeneelen M, Ritschel T, Tolboom J, Muchene L, van der Lubbe J, Izquierdo Gil A, Veldman D, Huizingh J, Verspuij J, Schmit-Tillemans S, Blokland S, de Man M, Roozendaal R, Fox CB, Schuitemaker H, Capelle M, Langedijk JPM, Zahn R, Brandenburg B. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen. NPJ vaccines. 2023; 8(1); 176. [PubMed: 37952003].
Van et al., 2018: Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN. A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen. NPJ vaccines. 2018; 3; 39. [PubMed: 30302281].
|
|
